Company intelligence / Profile preview

FIMECS, Inc.

Fujisawa, Kanagawa, Japanfimecs.com ↗

Ownership: Private
Employees: ~23
Development stage: Preclinical

Overview

FIMECS has developed a proprietary targeted protein degradation platform enabling the discovery of small molecule drugs against previously undruggable targets. Their lead program(s) are preclinical, with focus on oncology/immuno-oncology. The company was acquired by RaQualia Pharma in early 2024 to further leverage its technology for unmet medical needs.

Therapeutic areas: OncologyOther
Modalities: Small molecules (specifically proteolysis-targeting chimeras/PROTACs and targeted protein degraders)
Industry: Biotech

Drug pipeline

1 asset

FIM-001

Preclinical

Partnerships

Takeda Pharmaceutical Co., Ltd. – license agreement for use of IRAK-M and other assets since Feb.2018Academic collaboration with Kyoto University disclosed in September 2024 news release

Beyond the preview

Go deeper on FIMECS, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIMECS, Inc..

Explore the full profile